AstraZeneca Ends Late-Stage Lung Cancer Trial After Data Shows No Survival Benefit
AstraZeneca has stopped a Phase Three trial of an experimental bispecific antibody after interim results indicated the treatment would not improve survival, dealing a setback to the company’s plans for major revenue growth by the end of the decade.